Kim Tae-Su, Choi Ehn-Kyoung, Kim Jihyun, Shin Kyungha, Lee Sung-Pyo, Choi Youngjin, Jeon Joseph H, Kim Yun-Bae
Misuba RTech Co., Ltd., Asan, Korea.
College of Veterinary Medicine, Chungbuk National University, Cheongju, Korea.
Lab Anim Res. 2014 Sep;30(3):131-5. doi: 10.5625/lar.2014.30.3.131. Epub 2014 Sep 29.
Helicobacter pylori-eliminating effects of FEMY-R7, composed of fucoidan and evening primrose extract, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1×10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10 or 100 mg/kg FEMY-R7 for 2 weeks. In Campylobcter-like organism-detection test, FEMY-R7 markedly reduced the urease-positive reactivity. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with a capsule containing 150 mg FEMY-R7 for 8 weeks. FEMY-R7 significantly decreased both the Delta over baseline-value in urea breath test and the serum pepsinogens I and II levels. The results indicate that FEMY-R7 not only eliminates H. pylori from gastric mucosa of animals and humans, but also improves gastric function.
研究了由岩藻依聚糖和月见草提取物组成的FEMY-R7对小鼠和人类的根除幽门螺杆菌作用。雄性C57BL/6小鼠每隔2天通过胃内接种(1×10⁹CFU/小鼠)感染细菌3次,同时每天口服10或100mg/kg FEMY-R7,持续2周。在类弯曲杆菌检测试验中,FEMY-R7显著降低了尿素酶阳性反应性。在一项临床研究中,确诊感染幽门螺杆菌的人类受试者每天口服两次含有150mg FEMY-R7的胶囊,持续8周。FEMY-R7显著降低了尿素呼气试验中相对于基线值的Δ值以及血清胃蛋白酶原I和II水平。结果表明,FEMY-R7不仅能从动物和人类的胃黏膜中清除幽门螺杆菌,还能改善胃功能。